Altre lingue Autolus Therapeutics plc

Azioni

AUTL

US05280R1005

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
4 ^USD	-1,96%		-11,50%	-37,89%

25/04	I titoli azionari europei scambiati negli Stati Uniti come ricevute di deposito americane sono in modesto rialzo nelle contrattazioni del giovedì	MT
19/04	I titoli azionari europei scambiati negli Stati Uniti come ricevute di deposito americane hanno registrato una tendenza al rialzo nelle contrattazioni di venerdì, ma terminano la settimana in ribasso.	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	25/04
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO	24/04
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	23/04
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	19/04
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	18/04
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	11/04
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	08/04
European Equities Close Lower Tuesday; Eurozone Manufacturing at 3-Month Low; Mining Stocks Rally, Real Estate Drops	02/04
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	02/04
Autolus Therapeutics Gets European Agency Approval for Marketing Authorization Application for Leukemia Treatment	02/04
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02/04
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02/04
Autolus Therapeutics Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)	02/04
EARNINGS: EPE Special "cautiously optimistic"; RTW Biotech NAV rises	02/04
Autolus Therapeutics Appoints Mike Bonney as Chair	01/04
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	01/04
Autolus Therapeutics Announces Changes to its Board of Directors	01/04
Autolus Therapeutics Announces Changes to its Board of Directors	01/04
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	27/03
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	25/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Autolus Therapeutics plc

Azioni

AUTL

US05280R1005

Altre lingue

Filtri